CAJ | 학술논문

目的评价国内溴隐亭治疗垂体催乳素瘤的疗效和安全性.方法搜集国内溴隐亭与经蝶窦入路显微手术治疗催乳素瘤的病例对照试验文献,对符合纳入标准的研究使用统计软件RevMan 5.1.0完成荟萃分析.结果共纳入8篇回顾性对比分析文献研究,总计1 559例患者,平均随访时间6个月以上,利用随机效应模型进行荟萃分析,与经蝶窦入路显微手术组相比,溴隐亭组降低催乳素(PRL)分泌有效率的合并OR =0.80(95％ CI:O.38 ～1.67),P=0.55,不良反应发生率的合并OR=3.70(95％CI:0.61～22.29),P=0.15.结论国内的有限证据表明,与经蝶窦入路显微手术相比,口服溴隐亭在降低催乳素瘤患者血PRL水平和不良反应发生率方面差异没有统计学意义.
목적 평개국내추은정치료수체최유소류적료효화안전성.방법 수집국내추은정여경접두입로현미수술치료최유소류적병례대조시험문헌,대부합납입표준적연구사용통계연건RevMan 5.1.0완성회췌분석.결과 공납입8편회고성대비분석문헌연구,총계1 559례환자,평균수방시간6개월이상,이용수궤효응모형진행회췌분석,여경접두입로현미수술조상비,추은정조강저최유소(PRL)분비유효솔적합병OR =0.80(95％ CI:O.38 ～1.67),P=0.55,불량반응발생솔적합병OR=3.70(95％CI:0.61～22.29),P=0.15.결론 국내적유한증거표명,여경접두입로현미수술상비,구복추은정재강저최유소류환자혈PRL수평화불량반응발생솔방면차이몰유통계학의의.
Objective To evaluate the effectiveness and safety of bromocriptine on treating prolactinoma in China.Methods Case - controlled trials of bromocriptine on treating prolactinoma in China were collected,and systematic review and Meta - Analysis were conducted.Results A total of 8 case -control trials involving 1559 patients were included,and the average follow -up time was more than 6 months.As for the total effective rate and the incidence of side effects,no significant differences were found between bromocriptine and transsphenoidal microsurgery ( OR ＝ O.80,95％ CI:O.38 - 1.67,P ＝ O.55 ) or (OR =3.70,95％ CI:0.61 - 22.29,P =O.15),respectively. Conclusion Observational evidence supports that treatments of prolactinoma using bromocriptine compared to transsphenoidal microsurgery in China have no difference regarding the effective rate and the incidence of side effects.